SangStat Bets on Focus vs. Size
Up against Novartis, the Swiss marketing giant that now owns the $1.3 billion market for cyclosporine, SangStat insists that its disease management approach to organ transplantation is the right model at the right time.
You may also be interested in...
The transplantation market has changed considerably since Novartis (via its predecessor, Sandoz) launched the then-revolutionary selective immunosuppressant cyclosporin in 1983. Nowadays, clinicians and patients have many more treatment options--thanks largely to enhanced understanding of immunology--and thus the trend is strongly towards individualized therapy. In response to this shift, Novartis has given up pursuing radically new approaches to treatment and is concentrating on developing a product for every class of drug now used to treat graft recipients.
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.